1. 17‐Hydroxyprogesterone caproate in triplet pregnancy: an individual patient data meta‐analysis
- Author
-
Combs, CA, Schuit, E, Caritis, Lim, AC, Garite, TJ, Maurel, K, Rouse, D, Thom, E, Tita, AT, Mol, BWJ, and collaboration, A Global Obstetrics Network
- Subjects
Reproductive Medicine ,Biomedical and Clinical Sciences ,Pediatric ,Infant Mortality ,Clinical Research ,Prevention ,Clinical Trials and Supportive Activities ,Preterm ,Low Birth Weight and Health of the Newborn ,Perinatal Period - Conditions Originating in Perinatal Period ,Evaluation of treatments and therapeutic interventions ,6.1 Pharmaceuticals ,Reproductive health and childbirth ,Good Health and Well Being ,alpha-Hydroxyprogesterone Caproate ,Female ,Humans ,Hydroxyprogesterones ,Pregnancy ,Pregnancy ,Triplet ,Premature Birth ,Progestins ,Treatment Outcome ,17-Hydroxyprogesterone caproate ,multiple gestation ,preterm birth prevention ,progestogens ,triplet pregnancy ,Global Obstetrics Network (GONet) collaboration ,Medical and Health Sciences ,Obstetrics & Reproductive Medicine ,Reproductive medicine - Abstract
BackgroundPreterm birth complicates almost all triplet pregnancies and no preventive strategy has proven effective.ObjectiveTo determine, using individual patient data (IPD) meta-analysis, whether the outcome of triplet pregnancy is affected by prophylactic administration of 17-hydroxyprogesterone caproate (17OHPc).Search strategyWe searched literature databases, trial registries and references in published articles.Selection criteriaRandomised controlled trials (RCTs) of progestogens versus control that included women with triplet pregnancies.Data collection and analysisInvestigators from identified RCTs collaborated on the protocol and contributed their IPD. The primary outcome was a composite measure of adverse perinatal outcome. The secondary outcome was the rate of birth before 32 weeks of gestation. Other pre-specified outcomes included randomisation-to-delivery interval and rates of birth at
- Published
- 2016